Targeting immune suppressing myeloid-derived suppressor cells in oncology
- 20 March 2010
- journal article
- review article
- Published by Elsevier BV in Critical Reviews in Oncology/Hematology
- Vol. 77 (1), 12-19
- https://doi.org/10.1016/j.critrevonc.2010.02.004
Abstract
No abstract availableKeywords
This publication has 69 references indexed in Scilit:
- Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytesBritish Journal of Cancer, 2009
- Myeloid-derived suppressor cells as regulators of the immune systemNature Reviews Immunology, 2009
- Apoptosis of CD4+CD25high T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2Cancer Immunology, Immunotherapy, 2008
- Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapyCancer Immunology, Immunotherapy, 2008
- Microenvironmental regulation of metastasisNature Reviews Cancer, 2008
- Matrix Metalloproteinase-9 Is Required for Tumor Vasculogenesis but Not for Angiogenesis: Role of Bone Marrow-Derived Myelomonocytic CellsCancer Cell, 2008
- Abrogation of TGFβ Signaling in Mammary Carcinomas Recruits Gr-1+CD11b+ Myeloid Cells that Promote MetastasisCancer Cell, 2008
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002